Biosynexus Incorporated is a biopharmaceutical company that is developing a monoclonal antibody, pagibaximab, to prevent staphylococcal sepsis in very low birth weight (VLBW) infants in the setting of the neonatal intensive care unit (NICU). The company has two additional product candidates: lysostaphin for the treatment of life threatening staphylococcal infections and nisin a topical cream for treating serious skin infections.

Biosynexus' mission is bringing products to the market for the prevention and treatment of bacterial infections with emphasis on the prevention of staphylococcal infections in VLBW infants.

Staphylococcal infections occur commonly in VLBW infants who are admitted to a NICU after birth. These infections cause long term complications, increased hospital stays, increased costs of medical care, and some instances causes death. The antibiotic therapies necessary to treat these infections are associated with the development of antibiotic resistant bacteria which are becoming a serious and growing world wide problem. Preventing staphylococcal infections by vaccination is not possible in VLBW infants whose underdeveloped immune systems are incapable of mounting an antibody response to the vaccine.

Approximately 20,000 people die each year in the United States due to antibiotic resistant staphylococcal infections. These infections may occur in both healthy persons and in those who are otherwise more susceptible to infections because of a serious medical condition that weakens their defenses against bacteria. Hospitalized patients with catheters are at a heightened risk to develop such infections which are notoriously difficult to treat because staphylococci form a biofilm on the surface of the catheter which excludes antibiotics, preventing the eradication of the bacteria by the antibiotic.

Skin infections have been and remain a serious medical problem around the world. In particular, the appearance of resistant staphylococcal skin infections which do not respond to conventional antibiotics has led to loss of limbs and death as a consequence of an initial skin infection. Whereas effective antibiotics are available to treat skin infections, emergence of antibiotic resistant staphylococci is often observed and relying on conventional therapy to treat the infection becomes problematic.

Biosynexus is developing three products for the prevention and treatment of multi-drug resistant staphylococcal infections. The three lead products are pagibaximab, lysostaphin and nisin.

The Biosynexus management team is a diverse group of individuals with expertise in business, clinical research and product development. Meet our Management Team.